NCT04983823 Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)
| NCT ID | NCT04983823 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Baker Heart and Diabetes Institute |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 820 participants |
| Start Date | 2021-11-18 |
| Primary Completion | 2025-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 820 participants in total. It began in 2021-11-18 with a primary completion date of 2025-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors \>50 years old. The overall goal of this study to identify the feasibility and value of risk-guided medical therapy and exercise intervention in COVID-19 survivors.
Eligibility Criteria
Inclusion Criteria: 1. History of COVID-19 infection 2. Live within a geographically accessible area for follow-up Exclusion Criteria: 1. Valvular stenosis or regurgitation of \>moderate severity 2. History of previous heart failure (baseline New York Heart Association (NYHA) classification \>2) 3. Inability to acquire interpretable images (identified from baseline echo) 4. Contraindications to beta blockers or angiotensin-converting enzyme inhibitors 5. Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial 6. Already taking both angiotensin converting enzyme inhibitors/ angiotensin receptor blockers and beta blockers, or intolerance (or allergy) to both. 7. Mobility impairment that would impact participants' ability to perform exercise 8. Unable to provide written informed consent to participate in this study
Contact & Investigator
Thomas H Marwick, MD,PhD,MPH
PRINCIPAL INVESTIGATOR
Baker Heart and Diabetes Institute
Frequently Asked Questions
Who can join the NCT04983823 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 85 Years, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04983823 currently recruiting?
Yes, NCT04983823 is actively recruiting participants. Contact the research team at joel.smith@baker.edu.au for enrollment information.
Where is the NCT04983823 trial being conducted?
This trial is being conducted at Melbourne, Australia.
Who is sponsoring the NCT04983823 clinical trial?
NCT04983823 is sponsored by Baker Heart and Diabetes Institute. The principal investigator is Thomas H Marwick, MD,PhD,MPH at Baker Heart and Diabetes Institute. The trial plans to enroll 820 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.